Tirzepatide is a synthetic 39-amino acid peptide that functions as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It was engineered with a C18 fatty diacid moiety enabling albumin binding and an extended half-life. Tirzepatide represents the first dual incretin receptor agonist to receive clinical approval and is one of the most extensively investigated metabolic peptides in current pharmacological research.

Research has established Tirzepatide’s activity at both GIP and GLP-1 receptors and has investigated its superiority over GLP-1 mono-agonists in glycemic control and body-composition endpoints in large-scale clinical trials. Studies have examined its effects on pancreatic beta-cell function, hepatic glucose production, gastric emptying, appetite-regulating neuropeptide expression, and adipose tissue insulin sensitivity. Preclinical research has further investigated Tirzepatide’s effects on fatty liver disease, inflammation, and cardiovascular risk biomarkers.

Tirzepatide is a primary reference compound in incretin pharmacology research, metabolic biology, and type 2 diabetes research. This 10mg research preparation supports in vitro receptor binding studies, preclinical metabolic investigations, and pharmacological comparison studies examining GLP-1R and GIPR co-agonism.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.